SLC5A2 and diabetes mellitus: This finding led to the repurposing of this diabetes drug to combat heart failure, and recently the Food and Drug Administration (FDA) in the USA approved an SGLT2 inhibitor for the treatment of heart failure with reduced ejection fraction (HFrEF) in adults with or without diabetes5.